Merus

Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO Annual Meeting

2 June 2024 -- Utrecht, The Netherlands and Massachusetts, US -- Merus NV, a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced updated interim clinical data on MCLA-145 monotherapy and in combination with pembrolizumab were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in...
Uppsalalaan 17 3rd & 4th floor 3584 CT Utrecht The Netherlands

+31 85 016 2500